Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples